

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Aprepitant Injection (18ml:130mg) (the “**Product**”) developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.

The Product is a submicron emulsion injection of a neurokinin-1 (NK<sub>1</sub>) receptor antagonist, which can selectively bind to NK<sub>1</sub> receptors in the brain and antagonise the substance P to effectively prevent acute and delayed vomiting. The Product is indicated for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) in adult patients. Compared to oral formulations available in the market, the Product can be administered in a single dose with high bioavailability. When compared to fosaprepitant, the Product can effectively reduce the incidence of allergic reactions during clinical use as it does not contain polysorbate 80. In addition, the Product can be administered not only by intravenous infusion, but also by intravenous push, providing a more efficient and convenient medication option.

The Product is the seventh approved product from the Group’s nanotechnology platform, and the approval of the Product will further enrich the Group’s product portfolio for the treatment of cancer-related conditions.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 9 September 2024

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*